Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01195
|
|||||
| Drug Name |
Rabeprazole
|
|||||
| Synonyms |
2-(((4-(3-Methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole; 2-((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl)-1H-benzimidazole; 2-({[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methyl}sulfinyl)-1H-benzimidazole; 2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1H-benzimidazole; Aciphex (TN); CL23619; Dexrabeprazole; Eraloc; Eraloc (TN); LY307640; Pariet (TN); Rabeprazole (INN); Rabeprazole [BAN:INN]; Rabeprazole [INN:BAN]; Rablet (TN); Rebeprazole sodium
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Gastroesophageal reflux disease [ICD11:DA22] | Approved | [1] | |||
| Peptic ulcer [ICD11:DA61] | Approved | [1] | ||||
| Therapeutic Class |
Antiulcer Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C18H21N3O3S
|
|||||
| Canonical SMILES |
CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCCCOC
|
|||||
| InChI |
InChI=1S/C18H21N3O3S/c1-13-16(19-9-8-17(13)24-11-5-10-23-2)12-25(22)18-20-14-6-3-4-7-15(14)21-18/h3-4,6-9H,5,10-12H2,1-2H3,(H,20,21)
|
|||||
| InChIKey |
YREYEVIYCVEVJK-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 117976-89-3
|
|||||
| Pharmaceutical Properties | Molecular Weight | 359.4 | Topological Polar Surface Area | 96.3 | ||
| Heavy Atom Count | 25 | Rotatable Bond Count | 8 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 6 | |||
| XLogP |
1.9
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10066
,103370406
,104029616
,104308073
,118212884
,124659135
,125338815
,126525321
,126591137
,126655846
,126670688
,126670689
,129836330
,131295768
,134338014
,135040318
,137018746
,142316515
,142318546
,142519546
,14828218
,152034678
,160825170
,160964463
,162022428
,163092473
,163384417
,164339280
,164787748
,166650031
,170500544
,172080531
,178103864
,179116873
,29224100
,46386636
,46506366
,49681560
,49742702
,50064224
,50769860
,5392621
,57288826
,57322572
,7980480
,8153096
,85174502
,92308674
,93166177
,96025149
|
|||||
| ChEBI ID |
ChEBI:8768
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| References | ||||||
| 1 | Rabeprazole was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol. 2009 Jan;67(1):44-9. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.